z-logo
open-access-imgOpen Access
SC29EK, a Peptide Fusion Inhibitor with Enhanced α-Helicity, Inhibits Replication of Human Immunodeficiency Virus Type 1 Mutants Resistant to Enfuvirtide
Author(s) -
Toshio Naito,
Keisuke Izumi,
Eiichi Kodama,
Yasuko Sakagami,
Keiko Kajiwara,
Hiroki Nishikawa,
Kentaro Watanabe,
Stefan G. Sarafianos,
Shinya Oishi,
Nobutaka Fujii,
Masao Matsuoka
Publication year - 2009
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.01211-08
Subject(s) - enfuvirtide , gp41 , biology , peptide , virology , viral replication , lipid bilayer fusion , ritonavir , mutant , peptidomimetic , protease , wild type , reverse transcriptase , amino acid , microbiology and biotechnology , biochemistry , virus , rna , viral load , enzyme , genetics , epitope , antibody , antiretroviral therapy , gene
Peptides derived from the α-helical domains of human immunodeficiency virus (HIV) type 1 (HIV-1) gp41 inhibit HIV-1 fusion to the cell membrane. Enfuvirtide (T-20) is a peptide-based drug that targets the step of HIV fusion, and as such, it effectively suppresses the replication of HIV-1 strains that are either wild type or resistant to multiple reverse transcriptase and/or protease inhibitors. However, HIV-1 variants with T-20 resistance have emerged; therefore, the development of new and potent inhibitors is urgently needed. We have developed a novel HIV fusion inhibitor, SC34EK, which is a gp41-derived 34-amino-acid peptide with glutamate (E) and lysine (K) substitutions on its solvent-accessible site that stabilize its α-helicity. Importantly, SC34EK effectively inhibits the replication of T-20-resistant HIV-1 strains as well as wild-type HIV-1. In this report, we introduce SC29EK, a 29-amino-acid peptide that is a shorter variant of SC34EK. SC29EK blocked the replication of T-20-resistant HIV-1 strains and maintained antiviral activity even in the presence of high serum concentrations (up to 50%). Circular dichroism analysis revealed that the α-helicity of SC29EK was well maintained, while that of the parental peptide, C29, which showed moderate and reduced inhibition of wild-type and T-20-resistant HIV-1 strains, was lower. Our results show that the α-helicity in a peptide-based fusion inhibitor is a key factor for activity and enables the design of short peptide inhibitors with improved pharmacological properties.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here